Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson’s disease.

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson's diseasePrasinezumab is a potential first-in-class anti- ...